Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2019

Open Access 01-12-2019 | Alzheimer's Disease | Research

New therapeutic targeting of Alzheimer’s disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study

Authors: Marta Sochocka, Michał Ochnik, Maciej Sobczyński, Iwona Siemieniec, Beata Orzechowska, Piotr Naporowski, Jerzy Leszek

Published in: Journal of Neuroinflammation | Issue 1/2019

Login to get access

Abstract

Background

The lack of effective treatment for Alzheimer’s disease (AD) stems mainly from the incomplete understanding of AD causes. Neuroinflammation has emerged as an important component of AD pathology, and a vast number of experimental and clinical data indicated a crucial role for the activation of the innate immune system in disease promotion and symptom progression.

Methods

Clinical examinations of AD patients in a different stage of disease severity in correlation with the measurement of two innate immune reactions, i.e., peripheral blood leukocyte (PBLs) resistance to viral infection (vesicular stomatitis virus, VSV) ex vivo, and cytokines: TNF-α, IFN-γ, IL-1β, and IL-10, production with enzyme-linked immunosorbent assay (ELISA), have been investigated during this preliminary study before and after 4 weeks of oral treatment with dietary supplement proline-rich polypeptide complex (PRP) (120 μg of PRP/day). The potential effect of PRP on the distribution of PBLs’ subpopulations has been specified.

Results

We have found a deficiency in innate immune response in AD patients. It was demonstrated for the first time that the degree of PBLs resistance to VSV infection was closely related to the stage of clinical severity of AD. Our study showed significant differences in cytokine production which pointed that in AD patients innate immune mechanisms are impaired. Administration of PRP to our patients increased innate immune response of PBLs and declined pro- and anti-inflammatory cytokine production, thus subduing the excessively developed inflammatory response, especially among patients with high severity of AD. PRP did not exhibit a pro-proliferative activity. It was showed, however, significant influence of PRP on the distribution of PBLs’ subpopulations.

Conclusion

The findings mentioned above might be crucial in the context of potential application of immunomodulatory therapy in AD patients and indicated PRP as a potential target for future treatments in neuroinflammatory diseases like AD.
Appendix
Available only for authorised users
Literature
1.
2.
Beason-Held LL, Goh JO, An Y, et al. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci. 2013;33(46):18008–14.PubMedPubMedCentralCrossRef
3.
4.
Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–9.PubMedCrossRef
5.
Blach-Olszewska Z, Zaczynska E, Gustaw-Rothenberg K, et al. The innate immunity in Alzheimer disease- relevance to pathogenesis and therapy. Curr Pharm Des. 2015;21(25):3582–8.PubMedCrossRef
6.
7.
8.
Orzechowska B, Antoszków Z, Błach-Olszewska Z. Individual differentiation of innate antiviral immunity in humans; the role of endogenous interferons and tumor necrosis factor in the immunity of leukocytes. Arch Immunol Ther Exp. 2003;51(1):51–60.
9.
Paradowska E, Błach-Olszewska Z, Sender J, Jarosz W. Antiviral nonspecific immunity of human placenta at term: possible role of endogenous tumor necrosis factors and interferons. J Interferon Cytokine Res. 1996;16(11):941–8.PubMedCrossRef
10.
Jatczak B, Leszek J, Siemieniec I, et al. Age- and disease-related innate immunity of human leukocytes ex vivo. Exp Gerontol. 2012;47(1):8–13.PubMedCrossRef
11.
Tomczyk T, Wróbel G, Chaber R, et al. Immune consequences of in vitro infection of human peripheral blood leukocytes with vesicular stomatitis virus. J Innate Immun. 2018;10(2):131–44.PubMedPubMedCentralCrossRef
12.
Zaczynska E, Duś D, Paprocka M, Błach-Olszewska Z. Resistance of human leukocytes to vesicular stomatitis virus infection as one of the innate antiviral immune activities; participation of cell subpopulations. Folia Histochem Cytobiol. 2008;46(1):39–43.PubMedCrossRef
13.
Błach-Olszewska Z, Jatczak B, Rak A, et al. Production of cytokines and stimulation of resistance to viral infection in human leukocytes by Scutellaria baicalensis flavones. J Interferon Cytokine Res. 2008;28(9):571–81.PubMedCrossRef
14.
Sochocka M, Zaczyńska E, Taboł A, et al. The influence of donepezil and EGb 761 on the innate immunity of human leukocytes: effect on the NF-κB system. Int Immunopharmacol. 2010;10(12):1505–13.PubMedCrossRef
15.
Sochocka M, Taboł A, Sobczyński M, et al. Innate antiviral immunity of human PBLs and immunoregulatory activity of EGb 761. Cent Eur J Biol. 2014;9(4):359–66.
16.
Alzheimer’s Association. Alzheimer’s Association report. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325–73.CrossRef
17.
Bagwe S, Tharappel LJP, Kaur G, Buttar HS. Bovine colostrum: an emerging nutraceutical. J Complement Integr Med. 2015;12(3):175–85.PubMedCrossRef
18.
Kruzel ML, Janusz M, Lisowski J, et al. Towards an understanding of biological role of colostrinin peptides. J Mol Neurosci. 2001;17(3):379–89.PubMedCrossRef
19.
Jatczak B, Gejdel E, Pajak J, et al. Study on risk factors for transplacental viral infections; effect of bacterial factors and double viral infections on virus replication in placenta and amniotic membranes. Placenta. 2001;22(4):360–71.PubMedCrossRef
20.
Orzechowska B, Janusz M, Domaraczenko B, Błach-Olszewska Z. Antiviral effect of proline-rich polypeptide in murine resident peritoneal cells. Acta Virol. 1998;42(2):75–8.PubMed
21.
Janusz M, Zabłocka A. Colostrinin: a proline-rich polypeptide complex of potential therapeutic interest. Cell Mol Biol (Noisy-le-grand). 2013;59(1):4–11.
22.
Janusz M, Zabłocka A. Colostral proline-rich polypeptides--immunoregulatory properties and prospects of therapeutic use in Alzheimer’s disease. Curr Alzheimer Res. 2010;7(4):323–33.PubMedCrossRef
23.
Sochocka M, Zaczyńska E, Leszek J, et al. Effect of donepezil on innate antiviral immunity of human leukocytes. J Neurol Sci. 2008;273(1–2):75–80.PubMedCrossRef
24.
Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227(5259):680–5.PubMedCrossRef
25.
26.
Sochocka M, Diniz BS, Leszek J. Inflammatory response in the CNS: friend or foe? Mol Neurobiol. 2017;54(10):8071–89.PubMedCrossRef
27.
28.
Le Page A, Dupuis G, Frost EH, et al. Role of the peripheral innate immune system in the development of Alzheimer’s disease. Exp Gerontol. 2018;1(107):59–66.
29.
Koyama A, O’Brien J, Weuve J, et al. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68(4):433–40.PubMedCrossRef
30.
Ng A, Tam WW, Zhang MW, et al. IL-1β, IL-6, TNF-α and CRP in elderly patients with depression or Alzheimer’s disease: systematic review and meta-analysis. Sci Rep. 2018;8(1):12050.PubMedPubMedCentralCrossRef
31.
Lai KSP, Liu CS, Rau A, et al. Peripheral inflammatory markers in Alzheimer’s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017;88(10):876–82.PubMedCrossRef
32.
Arosio B, D’Addario C, Gussago C, et al. Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly. Biomed Res Int. 2014;2014:169203.PubMedPubMedCentralCrossRef
33.
34.
Ciaramella A, Bizzoni F, Salani F, et al. Increased pro-inflammatory response by dendritic cells from patients with Alzheimer’s disease. J Alzheimers Dis. 2010;19(2):559–72.PubMedCrossRef
35.
Le Page A, Lamoureux J, Bourgade K, et al. Polymorphonuclear neutrophil functions are differentially altered in amnestic mild cognitive impairment and mild Alzheimer’s disease patients. J Alzheimers Dis. 2017;60(1):23–42.PubMedCrossRef
36.
Chen S-H, Bu X-L, Jin W-S, et al. Altered peripheral profile of blood cells in Alzheimer disease: a hospital-based case-control study. Medicine (Baltimore). 2017;96(21):e6843.CrossRef
37.
Richartz-Salzburger E, Batra A, Stransky E, et al. Altered lymphocyte distribution in Alzheimer’s disease. J Psychiatr Res. 2007;41(1–2):174–8.PubMedCrossRef
38.
Zimecki M. A proline-rich polypeptide from ovine colostrum: Colostrinin with immunomodulatory activity. In: Bösze Z, editor. Bioactive components of Milk. New York: Springer; 2008. p. 241–50.CrossRef
39.
Starościk K, Janusz M, Zimecki M, et al. Immunologically active nonapeptide fragment of a proline-rich polypeptide from ovine colostrum: amino acid sequence and immunoregulatory properties. Mol Immunol. 1983;20(12):1277–82.PubMedCrossRef
40.
Zabłocka A, Janusz M, Rybka K, et al. Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur Cytokine Netw. 2001;12(3):462–7.PubMed
41.
Kruzel ML, Polanowski A, Wilusz T, et al. The alcohol-induced conformational changes in casein micelles: a new challenge for the purification of colostrinin. Protein J. 2004;23(2):127–33.PubMedCrossRef
42.
Zimecki M, Artym J. Therapeutic properties of proteins and peptides from colostrum and milk. Postepy Hig Med Dosw (Online). 2005;59:309–23.
43.
Inglot AD, Janusz M, Lisowski J. Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch Immunol Ther Exp. 1996;44(4):215–24.
44.
Leszek J, Inglot AD, Janusz M, et al. Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Arch Immunol Ther Exp. 1999;47(6):377–85.
45.
Leszek J, Inglot AD, Janusz M, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer’s disease. Med Sci Monit. 2002;8(10):PI93–6.PubMed
46.
Szaniszlo P, German P, Hajas G, et al. New insights into clinical trial for Colostrinin in Alzheimer’s disease. J Nutr Health Aging. 2009;13(3):235–41.PubMedCrossRef
47.
Zabłocka A, Janusz M. Effect of the proline-rich polypeptide complex/colostrinin™ on the enzymatic antioxidant system. Arch Immunol Ther Exp. 2012;60(5):383–90.CrossRef
48.
Zabłocka A, Siednienko J, Mitkiewicz M, et al. Proline-rich polypeptide complex (PRP) regulates secretion of inflammatory mediators by its effect on NF-kappaB activity. Biomed Pharmacother. 2010;64(1):16–20.PubMedCrossRef
49.
Galani IE, Andreakos E. Neutrophils in viral infections: current concepts and caveats. J Leukoc Biol. 2015;98(4):557–64.PubMedCrossRef
50.
51.
Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;21(5):508.
52.
Boldogh I, Kruzel ML. Colostrinin: an oxidative stress modulator for prevention and treatment of age-related disorders. J Alzheimers Dis. 2008;13(3):303–21.PubMedCrossRef
53.
Daher KA, Selsted ME, Lehrer RI. Direct inactivation of viruses by human granulocyte defensins. J Virol. 1986;60(3):1068–74.PubMedPubMedCentral
Metadata
Title
New therapeutic targeting of Alzheimer’s disease with the potential use of proline-rich polypeptide complex to modulate an innate immune response - preliminary study
Authors
Marta Sochocka
Michał Ochnik
Maciej Sobczyński
Iwona Siemieniec
Beata Orzechowska
Piotr Naporowski
Jerzy Leszek
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2019
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-019-1520-6

Other articles of this Issue 1/2019

Journal of Neuroinflammation 1/2019 Go to the issue

Short report

Myosin1f-mediated neutrophil migration contributes to acute neuroinflammation and brain injury after stroke in mice

Research

Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease

Research

Epigenetic suppression of liver X receptor β in anterior cingulate cortex by HDAC5 drives CFA-induced chronic inflammatory pain

Research

Glial activation and inflammation along the Alzheimer’s disease continuum

Research

Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease

Research

Visualizing neuroinflammation with fluorescence and luminescent lanthanide-based in situ hybridization